TARS (tarsusrx.com) רווח נקי למניה (EPS TTM)

The success of Tarsus Pharmaceuticals (TARS) depends on the commercial takeoff of Xdemvy and the control of marketing expenses during the drug's rollout to pharmacies. The rolling 12-month net income per share visualizes the operational trend, where -15.04 serves as the current metric level. The company's revenues are based on the sale of innovative drops to ophthalmology centers and patients, paid via insurance policies or personal funds.

For Tarsus Pharmaceuticals (TARS), which integrates AI into the development of ophthalmological drugs, this metric serves as an indicator of the efficiency of innovation capitalization. By analyzing the 12-month net income per share chart, an investor assesses the final earnings distributed per share, allowing them to filter out market noise and understand the extent to which the automation of drop synthesis converts into real shareholder value.